HEPATOCELLULAR CARCINOMA

This early-stage trial tested a new treatment called ET140203 T cells for adults with advanced liver cancer that had not responded to other therapies. The treatment uses a patient's own immune cells, modified to target cancer cells. The study was stopped early after enrolling onl…

This study aimed to see if adding electromagnetic fields to the drug regorafenib could help people with advanced liver cancer live longer without their cancer growing. Only 2 people joined before the study was stopped early. The treatment was for patients who had already tried ot…

This study tested two immunotherapy drugs, durvalumab and tremelimumab, in 8 people with liver cancer who were waiting for a liver transplant. The goal was to see if the drugs could safely shrink tumors and control the disease without causing organ rejection. The trial was stoppe…

This study tested a new drug called OC-001, given alone or with an immunotherapy drug (Avelumab), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The study was stopped early and involved 73 participants with v…

This study tested a new drug (SOT101) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combination could shrink tumors. The study was stopped early, and participants were expected to need ongoing…

This study aimed to compare two standard first-line treatments for people with large, intermediate-stage liver cancer (HCC): a combination of immunotherapy (atezolizumab) and targeted therapy (bevacizumab) versus local procedures (TACE or TARE). Only one person enrolled before th…

This study tested a combination of three drugs—nivolumab, tadalafil, and vancomycin—in adults with liver cancer or liver tumors that spread from colorectal or pancreatic cancer. The goal was to see if the treatment could shrink tumors. The study was stopped early, but the results…

This early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors (like sarcoma, kidney cancer, or melanoma) that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated e…

This study looked at adding a targeted drug (donafenib) to a liver-directed therapy (HAIC-TACE) for people with advanced liver cancer that couldn't be surgically removed. The goal was to see if the combination helped control the cancer longer. The trial was stopped early and only…

This study tested whether adding another drug (BMS-986253 or cabiralizumab) to the immunotherapy nivolumab could shrink tumors better than nivolumab alone in people with advanced liver cancer. The trial was stopped early and only enrolled 13 participants, so results are limited. …

This study tested a new drug called SD-101, given directly into the liver's blood supply, along with standard immunotherapy drugs, for people with two types of liver cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma). The goal was to find a safe dose and see if…

This study tested a combination of two drugs (lenvatinib and VIC-1911) in 5 adults with advanced liver cancer that no longer responded to lenvatinib alone. The goal was to see if the combo was safe and could slow cancer growth. The trial was terminated early, so results are limit…

This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so resul…

This study looked at whether tiny bits of genetic material (extracellular RNA) found in the blood can help doctors diagnose liver cancer or other liver diseases. Researchers planned to enroll about 1,865 people with liver cancer, bile duct cancer, cirrhosis, or chronic liver dise…

This study tested whether combining a medical GPS tracking system with a special dye (ICG) could help doctors take more accurate liver biopsies in people with suspected liver cancer. Seven adults who needed a liver biopsy received the dye 24 hours before the procedure, and doctor…

This pilot study tested a software called BioTraceIO 360, designed to help doctors plan and monitor liver tumor ablation (a procedure that destroys tumors with heat). The study aimed to enroll 30 people with liver cancer, but was terminated early with only 4 participants. The goa…

This study tested a special scan (SPECT/CT) to measure how well the liver works in 41 people with liver cancer who were getting radiation or surgery. The goal was to see if the scan could track changes in healthy liver tissue before, during, and after treatment. The study was sto…

This study aimed to see if certain immune cell markers could predict which patients with advanced liver cancer would respond to a combination of immunotherapy drugs (Atezolizumab and Bevacizumab). Researchers planned to measure these markers before and after treatment in about 4 …

This study aimed to create a registry of tissue and blood samples from 1,000 people undergoing surgery or biopsy for liver or bile duct tumors. The samples were stored for future research to better understand these cancers and develop new treatments. The study was terminated earl…